NEGR1 and Seizure: To improve on the specificity and clinical value of the identified traits, a follow-up application of MR with specific expression/protein quantitative loci (tissue/cell type e/pQTL as applied in T1D drug candidate discovery [21] with genes such as CADPS, NTM and NEGR1 could further reveal molecular and translational insights towards ASD heterogeneity including the high vulnerability subgroup characterized by seizures [15].